Bell Rock Capital’s Novartis NVS Stock Holding History

Bell Rock Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,337	Closed	-$127K	–	217
2019 Q4	$127K	Sell	1,337 -5	-0.4%	-$449	0.11%	142
2019 Q3	$117K	Hold	1,342	–	–	0.1%	140
2019 Q2	$123K	Buy	1,342 +486	+57%	+$41.1K	0.11%	141
2019 Q1	$74K	Buy	856 +850	+14,167%	+$68.2K	0.04%	198
2018 Q4	$0	Buy	+6	New	+$467	﹤0.01%	456

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bell Rock Capital's NVS Position: Q1 2020 in Review

Bell Rock Capital sold out of Novartis (NVS) in Q1 2020, closing a stake of 1,337 shares — an estimated $127K sold.

Bell Rock Capital first reported a position in NVS in Q4 2018 and held it in 5 quarters. The position peaked at $127K in Q4 2019. 1,133 funds tracked by Wall St. Rank hold NVS as of Q1 2020.

Bell Rock Capital reported no remaining Novartis position as of Q1 2020 after selling out during the quarter.
Bell Rock Capital sold 1,337 Novartis shares in Q1 2020, an estimated $127K.
Bell Rock Capital first reported a position in Novartis in Q4 2018 and held it in 5 quarters.
Bell Rock Capital's Novartis position peaked at $127K in Q4 2019.
1,133 funds tracked by Wall St. Rank held Novartis as of Q1 2020.

Based on Bell Rock Capital's 13F filing for Q1 2020, filed 7 May 2020.